Bionik Laboratories (OTCMKTS:BNKL) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of Bionik Laboratories (OTCMKTS:BNKL) from a hold rating to a buy rating in a report issued on Tuesday, ValuEngine reports.

Shares of OTCMKTS BNKL opened at $1.99 on Tuesday. Bionik Laboratories has a 12 month low of $1.01 and a 12 month high of $100.00. The stock has a 50 day moving average of $1.82 and a 200-day moving average of $2.80.

About Bionik Laboratories

Bionik Laboratories Corp., a robotics company, focuses on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The company specializes in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products.

Further Reading: How is inflation measured?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Bionik Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionik Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.